Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Ricky Goldwasser maintains an Equal-Weight rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $6 to $8.
July 17, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on GoodRx Holdings and raises the price target from $6 to $8. This could potentially lead to a positive sentiment among investors.
The raised price target by Morgan Stanley indicates a positive outlook for GoodRx Holdings. This could potentially lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100